 |
|
COMMENTS AND OPINIONS
Tissue Plasminogen Activator Does Not Benefit Most Eligible Patients With Stroke
Maarten G. Lansberg, MD, PhD;
Neil E. Schwartz, MD, PhD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Liang et al, in their review of legal issues related to intravenous tissue plasminogen activator (tPA), make the point that tPA "is efficacious and can result in highly improved outcomes for a majority of eligible patients."1 Although tPA results in improved outcome, it unfortunately does so in only a minority of cases. The percentage of patients who experience benefit depends on the chosen efficacy measure. This percentage, however, lies well below the 50% mark for all relevant measures. When considering the traditional efficacy measure of a favorable outcome, namely a modified Rankin Scale score of 0 or 1 at 90 days, only 13% of patients with stroke treated with tPA benefit. This is based on data from the National Institute of Neurological Disorders and Stroke trial in which 26% of placebo-treated patients achieved this outcome vs 39% of tPA-treated patients.2 . . . [Full Text of this Article]AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Review of Tissue Plasminogen Activator, Ischemic Stroke, and Potential Legal Issues
Bryan A. Liang, Robert Lew, and Justin A. Zivin
Arch Neurol. 2008;65(11):1429-1433.
ABSTRACT
| FULL TEXT
Number Needed to Treat Estimates Incorporating Effects Over the Entire Range of Clinical Outcomes: Novel Derivation Method and Application to Thrombolytic Therapy for Acute Stroke
Jeffrey L. Saver
Arch Neurol. 2004;61(7):1066-1070.
ABSTRACT
| FULL TEXT
RELATED LETTER
Tissue Plasminogen Activator Does Not Benefit Most Eligible Patients With Stroke—Reply
Bryan A. Liang, Robert Lew, and Justin A. Zivin
Arch Neurol. 2009;66(4):541.
EXTRACT
| FULL TEXT
|
